Richard C Dart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/473720/publications.pdf

Version: 2024-02-01

		76326	6	6911
127	6,497	40		78
papers	citations	h-index		g-index
130	130	130		5065
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	Clustering patterns in polysubstance mortality in the United States in 2017: a multiple correspondence analysis of death certificate data. Annals of Epidemiology, 2023, 77, 119-126.	1.9	2
2	Metabolomic markers predictive of hepatic adaptation to therapeutic dosing of acetaminophen. Clinical Toxicology, 2022, 60, 221-230.	1.9	5
3	Control of venom-induced tissue injury in copperhead snakebite patients: a post hoc sub-group analysis of a clinical trial comparing F(ab') ₂ to Fab antivenom. Clinical Toxicology, 2022, 60, 521-523.	1.9	2
4	Adverse Events Related to Accidental Unintentional Ingestions From Cough and Cold Medications in Children. Pediatric Emergency Care, 2022, 38, e100-e104.	0.9	2
5	Association Between Prescription Opioid Therapy for Noncancer Pain and Hepatitis C Virus Seroconversion. JAMA Network Open, 2022, 5, e2143050.	5.9	1
6	Comparison of hospital claims and poison center data to evaluate health impact of opioids, cannabis and synthetic cannabinoids. American Journal of Emergency Medicine, 2022, 53, 150-153.	1.6	2
7	The association between the availability of over the counter codeine and the prevalence of non-medical use. European Journal of Clinical Pharmacology, 2022, 78, 1011-1018.	1.9	5
8	The Roles of Antidotes in Emergency Situations. Emergency Medicine Clinics of North America, 2022, 40, 381-394.	1.2	3
9	Prevalence and description of kratom (<i>Mitragyna speciosa</i>) use in the United States: a crossâ€sectional study. Addiction, 2021, 116, 176-181.	3.3	81
10	Nonmedical use of benzodiazepines and Zâ€drugs in the UK. British Journal of Clinical Pharmacology, 2021, 87, 1676-1683.	2.4	14
11	Kratom use in the United States: Response to Grundmann <i>et al</i> Addiction, 2021, 116, 203-204.	3.3	3
12	An evaluation of online discussion relating to nonmedical use of prescription opioids within the UK. British Journal of Clinical Pharmacology, 2021, 87, 1637-1646.	2.4	4
13	The Genomics of Elevated ALT and Adducts in Therapeutic Acetaminophen Treatment: a Pilot Study. Journal of Medical Toxicology, 2021, 17, 160-167.	1.5	5
14	Impact of product safety changes on accidental exposures to liquid laundry packets in children. Clinical Toxicology, 2021, 59, 392-399.	1.9	1
15	Nonâ€medical use of benzodiazepines and GABA analogues in Europe. British Journal of Clinical Pharmacology, 2021, 87, 1684-1694.	2.4	7
16	Trends in adverse events and related health-care facility utilization from cough and cold medication exposures in children. Clinical Toxicology, 2021, 59, 351-354.	1.9	3
17	Measuring prescription opioid misuse and its consequences. British Journal of Clinical Pharmacology, 2021, 87, 1647-1653.	2.4	14
18	Cohort profile: development and characteristics of a retrospective cohort of individuals dispensed prescription opioids for non-cancer pain in British Columbia, Canada. BMJ Open, 2021, 11, e043586.	1.9	5

#	Article	IF	Citations
19	Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries. Frontiers in Psychiatry, 2021, 12, 676224.	2.6	10
20	Drug product dispensing and estimates of use in a general population survey as a signal detection problem. Pharmacoepidemiology and Drug Safety, 2021, 30, 1132-1139.	1.9	6
21	Pediatric Fatalities Associated With Over-the-Counter Cough and Cold Medications. Pediatrics, 2021, 148, .	2.1	11
22	Prescription opioid treatment for non-cancer pain and initiation of injection drug use: large retrospective cohort study. BMJ, The, 2021, 375, e066965.	6.0	15
23	Web-Based Discussion and Illicit Street Sales of Tapentadol and Oxycodone in Australia: Epidemiological Surveillance Study. JMIR Public Health and Surveillance, 2021, 7, e29187.	2.6	6
24	Adverse events associated with diphenhydramine in children, 2008–2015. Clinical Toxicology, 2020, 58, 99-106.	1.9	13
25	Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation Strategy. Pain Medicine, 2020, 21, 92-100.	1.9	4
26	Medication Errors From Over-the-Counter Cough and Cold Medications in Children. Academic Pediatrics, 2020, 20, 327-332.	2.0	10
27	Kratom (Mitragyna Speciosa) Liver Injury: A Comprehensive Review. Drugs, 2020, 80, 263-283.	10.9	41
28	Tramadol non-medical use in Four European countries: A comparative analysis. Drug and Alcohol Dependence, 2020, 217, 108367.	3.2	15
29	Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER. Pain Medicine, 2020, 21, 3660-3668.	1.9	7
30	The impact of the prescription opioid epidemic on young children: Trends and mortality. Drug and Alcohol Dependence, 2020, 211, 107924.	3.2	8
31	Online Conversation Monitoring to Understand the Opioid Epidemic: Epidemiological Surveillance Study. JMIR Public Health and Surveillance, 2020, 6, e17073.	2.6	8
32	Opioid discontinuation as an institutional mandate: Questions and answers on why we wrote to the Centers for Disease Control and Prevention. Substance Abuse, 2019, 40, 466-468.	2.3	13
33	Transition to two-bag intravenous acetylcysteine for acetaminophen overdose: a poison center's experience. Clinical Toxicology, 2019, 57, 217-218.	1.9	6
34	Opioid discontinuation as an institutional mandate: Questions and answers on why we wrote to the Centers for Disease Control and Prevention. Substance Abuse, 2019, 40, 4-6.	2.3	7
35	Nonmedical use of alprazolam in the UK: Results from a nationally representative survey. British Journal of Clinical Pharmacology, 2019, 85, 1841-1845.	2.4	8
36	Brief Report: Characterization of Marijuana Use in US College Students by State Marijuana Legalization Status as Reported to an Online Survey. American Journal on Addictions, 2019, 28, 266-269.	1.4	7

#	Article	IF	CITATIONS
37	The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune $F(ab\hat{E}^1)$ 2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Annals of Emergency Medicine, 2019, 74, 439-449.	0.6	11
38	Causal inference for evaluating prescription opioid abuse using trendâ€inâ€trend design. Pharmacoepidemiology and Drug Safety, 2019, 28, 716-725.	1.9	2
39	Commentary on Mintz et al . (2019): Unintended or intended? Coming to grips with the opioid crisis. Addiction, 2019, 114, 2160-2161.	3.3	1
40	Scoring the best deal: Quantity discounts and street price variation of diverted oxycodone and oxymorphone. Pharmacoepidemiology and Drug Safety, 2019, 28, 25-30.	1.9	11
41	Understanding multiâ€pill ingestion of prescription opioids: Prevalence, characteristics, and motivation. Pharmacoepidemiology and Drug Safety, 2019, 28, 117-121.	1.9	6
42	An Online Survey for Pharmacoepidemiological Investigation (Survey of Non-Medical Use of) Tj ETQq0 0 0 rgBT /	Overlock	10 Tf 50 542
43	Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System. Journal of Pain, 2018, 19, 439-453.	1.4	39
44	Unit-Dose Packaging and Unintentional Buprenorphine-Naloxone Exposures. Pediatrics, 2018, 141, e20174232.	2.1	14
45	Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics. Drug Safety, 2018, 41, 787-795.	3.2	49
46	Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care. Annals of Emergency Medicine, 2018, 71, 314-325.e1.	0.6	47
47	Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers. Journal of Substance Abuse Treatment, 2018, 84, 42-49.	2.8	13
48	Evaluation of the quality and value of data sources for postmarket surveillance of the safety of cough and cold medications in children. BMC Medical Research Methodology, 2018, 18, 175.	3.1	7
49	Consistency Between Opioid-Related Mortality Trends Derived From Poison Center and National Vital Statistics System, United States, 2006–2016. American Journal of Public Health, 2018, 108, 1639-1645.	2.7	22
50	Envenomations by Widow, Recluse, and Medically Implicated Spiders. Toxinology, 2018, , 379-412.	0.2	2
51	Law enforcementâ€derived data on gabapentin diversion and misuse, 2002â€2015: diversion rates and qualitative research findings. Pharmacoepidemiology and Drug Safety, 2017, 26, 1083-1086.	1.9	41
52	Safety Profile of Cough and Cold Medication Use in Pediatrics. Pediatrics, 2017, 139, .	2.1	30
53	Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug and Alcohol Dependence, 2017, 175, 140-145.	3.2	39
54	Changes in misuse and abuse of prescription opioids following implementation of Extendedâ€Release and Longâ€Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy. Pharmacoepidemiology and Drug Safety, 2017, 26, 1061-1070.	1.9	8

#	Article	IF	Citations
55	Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations. Journal of Pain, 2017, 18, 1287-1294.	1.4	6
56	Do abuse deterrent opioid formulations work?. Journal of Opioid Management, 2017, 13, 365-378.	0.5	16
57	Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids. Journal of Opioid Management, 2017, 13, 379-389.	0.5	1
58	Envenomations by Widow, Recluse, and Medically Implicated Spiders. Toxinology, 2017, , 1-26.	0.2	0
59	Paracetamol (acetaminophen) protein adduct concentrations during therapeutic dosing. British Journal of Clinical Pharmacology, 2016, 81, 562-568.	2.4	34
60	The prescription paradox of acetaminophen safety. Pharmacoepidemiology and Drug Safety, 2016, 25, 599-601.	1.9	6
61	Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System. Journal of Pain, 2016, 17, 745-752.	1.4	14
62	Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug and Alcohol Dependence, 2016, 168, 219-229.	3.2	44
63	The effect of an abuseâ€deterrent opioid formulation (OxyContin) on opioid abuseâ€related outcomes in the postmarketing setting. Clinical Pharmacology and Therapeutics, 2016, 100, 275-286.	4.7	57
64	Prescription opioid exposures and adverse outcomes among older adults. Pharmacoepidemiology and Drug Safety, 2016, 25, 539-544.	1.9	43
65	Diversion and Illicit Sale of Extended Release Tapentadol in the United States. Pain Medicine, 2016, 17, 1490-1496.	1.9	26
66	Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States. PLoS ONE, 2016, 11, e0167499.	2.5	35
67	Quantification of a biomarker of acetaminophen protein adducts in human serum by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry: Clinical and animal model applications. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2015. 985. 131-141.	2.3	33
68	Trends in abuse and misuse of prescription opioids among older adults. Drug and Alcohol Dependence, 2015, 149, 117-121.	3.2	144
69	Trends in Opioid Analgesic Abuse and Mortality in the United States. New England Journal of Medicine, 2015, 372, 241-248.	27.0	1,002
70	Abuse-Deterrent Formulations of Prescription Opioids. JAMA Psychiatry, 2015, 72, 849.	11.0	1
71	Poisoning in the United States: 2012 Emergency Medicine Report of the National Poison Data System. Annals of Emergency Medicine, 2015, 65, 416-422.	0.6	47
72	Using poison center exposure calls to predict prescription opioid abuse and misuseâ€related emergency department visits. Pharmacoepidemiology and Drug Safety, 2014, 23, 18-25.	1.9	32

#	Article	IF	Citations
73	Toxicity From Repeated Doses of Acetaminophen in Children. American Journal of Therapeutics, 2014, 21, 174-183.	0.9	36
74	Nonmedical Use of Tapentadol Immediate Release by College Students. Clinical Journal of Pain, 2014, 30, 685-692.	1.9	19
75	A randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administration. BMC Pharmacology & Expression (2014), 15, 39.	2.4	36
76	Medically Significant Late Bleeding After Treated Crotaline Envenomation: A Systematic Review. Annals of Emergency Medicine, 2014, 63, 71-78.e1.	0.6	34
77	Seasonal variation in suicidal behavior with prescription opioid medication. Journal of Affective Disorders, 2014, 158, 30-36.	4.1	11
78	Abuse and diversion of buprenorphine sublingual tablets and film. Journal of Substance Abuse Treatment, 2014, 47, 27-34.	2.8	84
79	Reduced Abuse, Therapeutic Errors, and Diversion Following Reformulation of Extended-Release Oxycodone in 2010. Journal of Pain, 2013, 14, 1122-1130.	1.4	93
80	Root Causes, Clinical Effects, and Outcomes of Unintentional Exposures to Buprenorphine by Young Children. Journal of Pediatrics, 2013, 163, 1377-1383.e3.	1.8	51
81	Surgical Considerations in the Management of Pit Viper Snake Envenomation. Journal of the American College of Surgeons, 2013, 217, 726-735.	0.5	41
82	A Randomized, Double-Blind, Placebo-Controlled Trial of a Highly Purified Equine F(ab)2 Antibody Black Widow Spider Antivenom. Annals of Emergency Medicine, 2013, 61, 458-467.	0.6	28
83	Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain, 2013, 154, 2287-2296.	4.2	187
84	Crowdsourcing Black Market Prices For Prescription Opioids. Journal of Medical Internet Research, 2013, 15, e178.	4.3	66
85	Intravenous Acetaminophen in the United States: latrogenic Dosing Errors. Pediatrics, 2012, 129, 349-353.	2.1	74
86	Effect of Therapeutic Doses of Acetaminophen (up to 4 g/day) on Serum Alanine Aminotransferase Levels in Subjects Consuming Ethanol: Systematic Review and Metaâ€analysis of Randomized Controlled Trials. Pharmacotherapy, 2012, 32, 784-791.	2.6	27
87	2011 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report. Clinical Toxicology, 2012, 50, 911-1164.	1.9	354
88	Assessment of the abuse of tapentadol immediate release: The first 24 months. Journal of Opioid Management, 2012, 8, 395-402.	0.5	45
89	Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emergency Medicine, $2011, 11, 2$.	1.9	167
90	Short-Term Outcomes After Fab Antivenom Therapy for Severe Crotaline Snakebite. Annals of Emergency Medicine, 2011, 57, 128-137.e3.	0.6	48

#	Article	IF	Citations
91	Tampering with Prescription Opioids: Nature and Extent of the Problem, Health Consequences, and Solutions. American Journal of Drug and Alcohol Abuse, 2011, 37, 205-217.	2.1	137
92	Post-marketing Surveillance of Methadone and Buprenorphine in the United States. Pain Medicine, 2010, 11, 1078-1091.	1.9	75
93	The Underrecognized Toll of Prescription Opioid Abuse on Young Children. Annals of Emergency Medicine, 2009, 53, 419-424.	0.6	110
94	Pediatric Fatalities Associated With Over the Counter (Nonprescription) Cough and Cold Medications. Annals of Emergency Medicine, 2009, 53, 411-417.	0.6	98
95	Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care. Annals of Emergency Medicine, 2009, 54, 386-394.e1.	0.6	101
96	Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: Expert Panel Report. Drug and Alcohol Dependence, 2009, 105, S65-S71.	3.2	25
97	Monitoring risk: Post marketing surveillance and signal detection. Drug and Alcohol Dependence, 2009, 105, S26-S32.	3.2	62
98	Does Therapeutic Use of Acetaminophen Cause Acute Liver Failure?. Pharmacotherapy, 2007, 27, 1219-1230.	2.6	123
99	Inhalational abuse of methanol products: elevated methanol and formate levels without vision loss. American Journal of Emergency Medicine, 2006, 24, 725-728.	1.6	22
100	Acetaminophen Poisoning: an Evidence-Based Consensus Guideline for Out-of-Hospital Management. Clinical Toxicology, 2006, 44, 1-18.	1.9	143
101	A Preliminary Study of Tricyclic Antidepressant (TCA) Ovine FAB for TCA Toxicity. Clinical Toxicology, 2006, 44, 275-281.	1.9	26
102	The Safety Profile of Sustained Release Paracetamol During Therapeutic Use and Following Overdose. Drug Safety, 2005, 28, 1045-1056.	3.2	8
103	Effectiveness of Delayed Use of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom. Journal of Toxicology: Clinical Toxicology, 2004, 42, 321-324.	1.5	14
104	North American snake envenomation: diagnosis, treatment, and management. Emergency Medicine Clinics of North America, 2004, 22, 423-443.	1.2	105
105	Rethinking the Toxic Methanol Level. Journal of Toxicology: Clinical Toxicology, 2003, 41, 793-800.	1.5	46
106	Resolution of compartment syndrome after rattlesnake envenomation utilizing non-invasive measures. Journal of Emergency Medicine, 2003, 24, 285-288.	0.7	66
107	Bites of Venomous Snakes. New England Journal of Medicine, 2002, 347, 347-356.	27.0	398
108	Time to reconstitution: purified Fab antivenom vs. unpurified IgG antivenom. Toxicon, 2001, 39, 729-731.	1.6	27

#	Article	IF	CITATIONS
109	A Randomized Multicenter Trial of Crotalinae Polyvalent Immune Fab (Ovine) Antivenom for the Treatment for Crotaline Snakebite in the United States. Archives of Internal Medicine, 2001, 161, 2030.	3.8	196
110	Efficacy, safety, and use of snake antivenoms in the United States. Annals of Emergency Medicine, 2001, 37, 181-188.	0.6	232
111	Attenuation of Verapamil-induced Myocardial Toxicity in an Ex-vivo Rat Model Using a Verapamil-specific Ovine Immunoglobin. Academic Emergency Medicine, 2001, 8, 950-955.	1.8	8
112	Tricyclic Antidepressants Directly Depress Human Myocardial Mechanical Function Independent of Effects on the Conduction System. Academic Emergency Medicine, 2001, 8, 1122-1127.	1.8	19
113	Neutralization ofLatrodectus mactansandL. hesperusVenom by Redback Spider (L. hasseltii) Antivenom. Journal of Toxicology: Clinical Toxicology, 2001, 39, 119-123.	1.5	47
114	Effect of Maximal Daily Doses of Acetaminophen on the Liver of Alcoholic Patients. Archives of Internal Medicine, 2001, 161, 2247.	3.8	115
115	Recurrent Coagulopathy After Antivenom Treatment of Crotalid Snakebite. Southern Medical Journal, 2000, 93, 562-566.	0.7	27
116	Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Annals of Emergency Medicine, 2000, 36, 126-132.	0.6	80
117	Accidental paracetamol overdosing and fulminant hepatic failure in children. Medical Journal of Australia, 2000, 173, 558-559.	1.7	5
118	Treatment of amitriptyline poisoning with ovine antibody to tricyclic antidepressants. Lancet, The, 1999, 354, 1614-1615.	13.7	22
119	Heat and motion stability of polyvalent Crotalidae antivenin, ovine Fab. Toxicon, 1998, 36, 377-382.	1.6	9
120	An Examination of Serial Urinalyses in Patients with North American Crotalid Envenomation. Journal of Toxicology: Clinical Toxicology, 1998, 36, 329-335.	1.5	4
121	Affinity-Purified, Mixed Monospecific Crotalid Antivenom Ovine Fab for the Treatment of Crotalid Venom Poisoning. Annals of Emergency Medicine, 1997, 30, 33-39.	0.6	140
122	Relationship of Venom Effects to Venom Antigen and Antivenom Serum Concentrations in a Patient With Crotalus atrox Envenomation Treated With a Fab Antivenom. Annals of Emergency Medicine, 1997, 30, 49-53.	0.6	54
123	Ovine Desipramine Antibody Fragments Reverse Desipramine Cardiovascular Toxicity in the Rat. Annals of Emergency Medicine, 1996, 27, 309-315.	0.6	30
124	Validation of a Severity Score for the Assessment of Crotalid Snakebite. Annals of Emergency Medicine, 1996, 27, 321-326.	0.6	143
125	Insufficient Stocking of Poisoning Antidotes in Hospital Pharmacies. JAMA - Journal of the American Medical Association, 1996, 276, 1508.	7.4	78
126	Effects of constriction bands on rattlesnake venom absorption: A pharmacokinetic study. Annals of Emergency Medicine, 1992, 21, 1086-1093.	0.6	35

#	Article	IF	CITATIONS
127	Efficacy of delayed administration of crotalid antivenom and crystalloid fluids. Toxicon, 1988, 26, 1218-1221.	1.6	9